Diabetes y Ronquido: El riesgo de desarrollar Diabetes tipo 2 en personas con ronquidos es 3 veces mayor que los no roncadores

En un estudio publicado en la revista Sleep Breath ( SleepBreath. 2011 Jan 27. Correlation of clinical profiles with obstructive sleep apnea and metabolic syndrome.Hasan A, Uzma N, Swamy TL, Shoba A, Kumar BS), se ha demostrado que los pacientes roncadores tienen 3 veces más de probabilidad de desarrollar Diabetes tipo 2 que los no roncadores.
aparato2El tratamiento con CPAP o Dispositivos de Avance mandibular mejoran el metabolismo de la glucosa tanto en pacientes diabéticos como no diabéticos con trastornos respiratorios del sueño, especialmente en los pacientes no obesos. (Eur Respir J 2009; 34: 243–260 Sleep, sleep-disordered breathing and metabolic consequences. P. Le´vy*, M.R. Bonsignore#,» and J. Eckel). Esto ha sido ratificado en el Congreso de la Sociedad Europea de Investigacion del Sueño (European Sleep Research Society, en Praga 31 Marzo 2011), por los Drs. Barbe (España), Simonds (Reino Unido) y Levy (Francia)quienes presentaron las alternativas de tratamiento en el ronquido y la apnea del sueño.Tratar los ronquidos es posible con los Dispositivos de Avance Mandibular del tipo Lirón.Las alternativas de tratamiento para estos problemas respiratorios son pocas, aunque gracias a los Dispositivos de Avance Mandibular, se dispone de una nueva alternativa eficaz para tratar estas alteraciones. En el congreso los representantes más importantes a nivel internacional presentan la efectividad de estos dispositivos. El Dr. Marklund de Suecia, y los doctores Dr. Ferran Barbe Illa y el Dr. Pedro Mayoral Sanz de España presentaron la conferencia Tratamiento de los pacientes con apnea obstructiva «provide basic knowledge about alternative and innovative treatment options with a focus on mandibular advancement devices » dando información relevante sobre esta innovadora y efectiva alternativa de tratamiento.
Sleep Breath. 2011 Jan 27.

Correlation of clinical profiles with obstructive sleep apnea and metabolic syndrome.

Hasan AUzma NSwamy TLShoba AKumar BS.

Department of Respiratory Medicine, Owaisi Hospital and Research Center, Hyderabad, India, 500 058, ashfaqhasanmd@gmail.com.

Abstract

BACKGROUND: Obstructive sleep apnea (OSA) is a common condition being increasingly recognized and is associated with many diseases. Few data are available for Indian patients and public health hazard of the condition continues to be seriously underestimated in this country. The objective of this study was to evaluate the prevalence of obesity, hypertension, diabetes mellitus, and hyperlipidemia (HLP) in a South Indian population with proven OSA.

METHODS: A retrospective analysis of data accrued in patients undergoing polysomnography (PSG) was undertaken. Two hundred thirty-four patients of either sex in the age of 54 ± 11 years who tested positive for OSA were compared with control group. An apnea-hypopnea index (AHI) of >5 in the presence of snoring and daytime somnolence was taken to define sleep apnea.

RESULTS: The mean AHI among the study group with OSA was 31.3 ± 18.6 as compared with 1.2 ± 0.5 in the control group. The BMI among patients with OSA was 36 ± 6 as compared with 29 ± 4 in comparison group (p < 0.001). Among the patients with OSA, 31% were having HLP, 59% were diabetics, and 86% were hypertensive. Subjects with PSG-proven OSA had significant levels of day time sleepiness, lack of concentration, changes in mood, morning headache, and dry mouth. Nonrestorative sleep, awakening with choking, nocturnal dyspnea, insomnia with frequent awakenings, nocturia, and diaphoresis were observed in (>80%) patients. A significant difference in the sleep efficiency (16%), sleep onset (14%), and mean saturation (9%) was observed in the study group as compared to the control group.

CONCLUSIONS: The risk of obesity, hypertension, diabetes mellitus, and HLP in OSA syndrome patients was almost three times more than that of the comparing group.

Leave a Reply

Your email address will not be published.